Article
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.
Pharmacological reports : PR - 1 Oct 2024
Brzdęk Michał, Zarębska-Michaluk Dorota, Kukla Michał, Janocha-Litwin Justyna, Dybowska Dorota, Janczewska Ewa, Lorenc Beata, Berak Hanna, Mazur Włodzimierz, Tudrujek-Zdunek Magdalena, Klapaczyński Jakub, Piekarska Anna, Sitko Marek, Laurans Łukasz, Parfieniuk-Kowerda Anna, Flisiak Robert
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) infection affects 50 million people worldwide with around 242,000 deaths annually, mainly due to complications such as cirrhosis and hepatocellular carcinoma (HCC). Portal hypertension (PH) caused by cirrhosis leads to severe consequences, including esophageal varices (EV). This study aimed to evaluate the effectiveness and safety of direct-acting antiviral (DAA) treatment in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
